Author’s Reply to Borg et al. Comment on: “EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars”

被引：0
作者：
Begoña Calvo
机构：
[1] University of the Basque Country,Pharmaceutical Technology Department, Faculty of Pharmacy
来源：
Drug Safety | 2014年 / 37卷
关键词：
Reference Product; Impurity Profile; Comparability Exercise; Safety Finding; Adverse Event Incidence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：125 / 126
页数：1
相关论文
共 7 条
  • [1] Casadevall B(2013)Pharmacovigilance and biosimilars: considerations, needs and challenges Expert Opin Biol Ther 13 1039-1047
  • [2] Edwards IR(undefined)undefined undefined undefined undefined-undefined
  • [3] Felix T(undefined)undefined undefined undefined undefined-undefined
  • [4] Graze PR(undefined)undefined undefined undefined undefined-undefined
  • [5] Litten JB(undefined)undefined undefined undefined undefined-undefined
  • [6] Strober BE(undefined)undefined undefined undefined undefined-undefined
  • [7] Warnock DG(undefined)undefined undefined undefined undefined-undefined
1